Article Text

Download PDFPDF
Adjuvant pelvic irradiation in patients with pathologic T2b carcinoma of the uterine cervix
  1. T Uno1,
  2. H Ito1,
  3. J Itami2,
  4. T Sato3,
  5. S Minoura3,
  6. S Yasuda1,
  7. T Aruga1,
  8. K Isobe1,
  9. N Shigematsu4 and
  10. A Kubo4
  1. 1 Department of Radiology, Chiba University, Chiba, Japan, Departments of
  2. 2 Radiation Therapy and
  3. 3 Obstetrics and Gynecology, International Medical Center of Japan, Tokyo, Japan, and
  4. 4 Department of Radiology, Keio University, Tokyo, Japan


Patients with cervical cancer are subject to postoperative adjuvant therapy if the histopathologic examination reveals parametrial involvement. This study evaluated the patterns of failure in patients with pathologic parametrial invasion (pT2b) treated with adjuvant pelvic irradiation. Between April 1985 and March 1997, 45 patients with pT2b cervical cancer were treated with postoperative pelvic irradiation. The median age was 52 years. Preoperative clinical stages were stage Ib in 8 patients, IIa in 4, and IIb in 33. Twenty-three patients had lymph node metastasis. The median total dose of whole pelvic radiation therapy was 50 Gy. Occurrence of pelvic failure or distant metastasis according to the nodal status was examined. None of the 22 patients without lymph node metastasis developed distant metastasis. Among the 23 node-positive patients, 6 developed distant metastasis as an initial failure site. The 5-year overall survival of the entire group was 78%. The actuarial distant metastasis-free rates at 5 years were 73% and 100% for those with and without pelvic lymph node metastasis, respectively (P = 0.016). Results support previous evidence for chemoradiation in patients with pelvic lymph node metastasis. However, it appears that the role of systemic chemotherapy for node-negative pT2b patients is yet to be established.

  • carcinoma
  • irradiation
  • lymph node metastasis
  • parametrium
  • uterine cervix

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.